Comparison of two different methods for measuring anti-mullerian hormone in a clinical series

Hyldgaard, Josephine; Bor, Pınar; Ingerslev, Hans Jakob; Tørring, Niels

doi:10.1186/s12958-015-0101-5

Cited by 30 publications

(16 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, since 2014, Elecsys Cobas (Roche), a new automated assay, was proven as a better method for measuring AMH . In our study, AMH was determined by an Elecsys Roche System based on the ECLIA technology, which was a fully automated assay and approved to be the optimal standard for biochemical assays …”

Section: Discussionmentioning

confidence: 99%

Exploration of the role of anti‐Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome

Lê

et al. 2019

Clinical Endocrinology

View full text Add to dashboard Cite

Objective: This study explores the role of anti-Mullerian hormone (AMH) and LH/ FSH ratio in diagnosis of polycystic ovary syndrome (PCOS). Methods: In this multicentre cross-sectional descriptive study, a total of 863 infertile women between 18 and 45 years were evaluated at three infertility centres in Vietnam and were recruited from June 2016 to June 2017. The patients were classified into two groups: Group I included 441 patients with PCOS (based on Rotterdam criteria consensus) and Group II included 422 non-PCOS women. Diagnosis of PCOS was established based on Rotterdam 2003 consensus, and exclusion criteria were ovarian disease (ovary cyst/tumour), history of ovarian surgery and ovarian failure. Results: At an optimum cut-off level of 32.79 pmol/L, AMH showed sensitivity and specificity of 78.50% and 75.83%, respectively, with the AUC 0.852 (95% CI: 0.826-0.875). The LH/FSH ratio had a similar AUC at the optimum cut-off of 1.33 (AUC = 0.867, 95% CI 0.842-0.889), which demonstrated a similar diagnosis value to AMH (P = 0.340). By using multiple logistic regression analysis, 1 ng/mL increase in AMH levels was associated with an increased risk of PCOS (OR = 1.63, 95% CI:1.506-1.764; P < 0.001). Similarly, one unit increase in LH/FSH ratio was associated with 14.433 times increased (95% CI: 9.302-22.395; P < 0.001) risk of PCOS. There were no significant differences between values of AMH and LH/FSH ratio in PCOS diagnosis, as the difference between the two AUCs was 0.013, 95% CI: −0.024 to 0.028 and P = 0.897. Conclusion:The value of serum AMH concentration has been found not significantly superior to LH/FSH ratio in PCOS diagnosis. Although these biomarkers separately are not adequate for PCOS diagnosis based on their own value, the combination of different endocrine factors including AMH, LH and LH/FSH ratio together with BMI and other anthropometric and clinical characteristics may offer extra value to establish the diagnosis of PCOS. K E Y W O R D Santi-Mullerian hormone, diagnostic value, LH/FSH ratio, polycystic ovary syndrome ACK N OWLED G EM ENTSWe thank the staff of the Hue Center for Reproductive Endocrinology and Infertility, Hue University Hospital for their excellent support.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploration of the role of anti‐Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome

Lê

et al. 2019

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…The main strength of the current study is the within-patient comparisons of changes in ovarian reserve markers. Another strength is the use of the fully automated Elecsys AMH Plus assay, which shows significantly lower betweenand intra-assay variability than previously used assays (Anckaert et al, 2016;Hyldgaard et al, 2015;Rustamov et al, 2014). It has been debated whether AMH concentrations vary significantly intra-and inter-cyclically; however, most studies agree that there is no clinically relevant intra-cyclic variation and even less inter-cyclic variation (La Marca et al, 2013;Lambert-Messerlian et al, 2016;Rustamov et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

“…AMH concentrations were analysed using the fully automated Elecsys AMH Plus assay (Roche Diagnostics, Germany) with low reported coefficients of variation of ≤4.4% for intermediate precision and ≤1.8% for repeatability based on a multicentre study (Anckaert et al, 2016). This is a more sensitive assay (limit of quantification 0.21 pmol/l) with a lower between-and intra-assay variability compared with previous assays (Cohen and Adams, 2011;Hyldgaard et al, 2015;Van Helden and Weiskirchen, 2015). FSH, LH and oestradiol were likewise analysed using Elecsys assays.…”

Section: Hormonal Analyses Of Blood Samplesmentioning

confidence: 99%

Ovarian reserve markers after discontinuing long-term use of combined oral contraceptives

Landersoe

Petersen

Sørensen

et al. 2020

Reproductive BioMedicine Online

View full text Add to dashboard Cite

“…In support of our results, van Helden and Weiskirchen [22] demonstrated good correlations between the Gen II ELISA and both the Access AMH assay and the new automated Elecsys system from Roche, both of which utilise the same monoclonal antibodies. The authors also demonstrated an extremely tight correlation between the Access and Elecsys assays, and these results were further [28] demonstrated a similar pattern of bias between the Gen II and Elecsys methods and proposed that this may be in part due to inter-laboratory bias with the Gen II method. The Gen II ELISA is a manual method and thus would be more prone to inter-operator bias and variation from a number of sources within the assay itself.…”

Section: Discussionmentioning

confidence: 74%

Assessment of the Access AMH assay as an automated, high-performance replacement for the AMH Generation II manual ELISA

Pearson¹

2016

Preprint

View full text Add to dashboard Cite

Background: The manual Generation II (Gen II) ELISA method used to measure Anti-Müllerian Hormone (AMH) from Beckman Coulter has recently been superseded by a fully automated AMH immunoassay. The aim of this study was to evaluate the performance of the Access AMH assay and directly compare it to the modified Gen II ELISA method. A secondary aim was to verify that the fertile age-related AMH range previously established using the Gen II ELISA could be used to interpret results from the new automated Access assay. Methods: The precision, stability, linearity, measurement range and detection limits were determined using recombinant AMH and patient serum samples. Different diluents and their effects on AMH concentration were compared. A correlation study was performed on patient samples to compare the Access AMH assay to the ELISA method on the Access2 and DxI800 analysers. The fertile AMH range was verified by comparing the 10th, 50th and 90th percentile values from both methods obtained from 489 natural conception pregnant women. Results: The Access AMH assay showed good performance across the measuring range for both intra-assay (CV 1.41-3.30 %) and inter-assay (CV 3.04-5.76 %) precision and acceptable sample stability. Dilution of the high concentration samples with the recommended diluent resulted in a small but significant downward shift in values. The assay was linear over the range of values recommended by the manufacturer, allowing for accurate reporting within the reported range. The two assay types were highly correlated (R 2 = 0.9822 and 0.9832 for Access2 and DxI800, respectively), and the differences observed between the Access2 and DxI800 analysers were within clinically acceptable ranges, indicating that the methods are interchangeable. Furthermore, we demonstrated that results from the published reference range for the Gen II ELISA correlate with those from the automated Access AMH assay. Conclusion: Here, we verified the published performance of the Access AMH assay and showed excellent correlation with the Gen II ELISA method. Moreover, we validated this correlation by confirming that the results from a fertile AMH reference range established using the preceding Gen II ELISA are interchangeable with the new automated Access AMH assay.

show abstract

Comparison of two different methods for measuring anti-mullerian hormone in a clinical series

Cited by 30 publications

References 8 publications

Exploration of the role of anti‐Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome

Exploration of the role of anti‐Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome

Ovarian reserve markers after discontinuing long-term use of combined oral contraceptives

Assessment of the Access AMH assay as an automated, high-performance replacement for the AMH Generation II manual ELISA

Contact Info

Product

Resources

About